T cells

[Kite] Kite, a Gilead Company announced the FDA has granted approval for Tecartus® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

[Journal of Nanobiotechnology] The authors exploited atovaquone/albumin nanoparticles to improve bioavailability and tumor targeting of atovaquone, enhancing the efficacy of anti-PD-1 therapy by normalizing tumor hypoxia.

[Cytotherapy] The authors revealed a strategy to modulate CAR T-cell activity at the protein level by employing Escherichia coli dihydrofolate reductase and trimethoprim as a chemical switch system.

[Journal of Controlled Release] In order to achieve successful transfection and protection from enzymatic degradation there is a need for a suitable carrier for cGAMP. Scientists described currently reported carriers for cGAMP, and correlate their characteristics to the effect they cause.

[Blood] Researchers identified adult diffuse large B-cell lymphoma (DLBCL) patients who received either an auto-hematopoietic cell transplant or CAR-T treatment with axicabtagene ciloleucelwhile in a partial remission by CT or PET scan.

[Cancer Medicine] SEC61G expression was analyzed using publicly available datasets. The association between SEC61G and disease prognosis was evaluated.